ErVimmune
Lyon · Founded 2019
About ErVimmune
ErVimmune creates novel immunotherapies that target non-conventional tumor antigens that are abnormally expressed in cancer cells and shared by tumors and patients, with a particular emphasis on meeting unmet medical requirements in cold malignancies.
Company Facts
- Founded: 2019
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $27.7M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2026)
- Website: https://ervimmune.com
- Phone: +33 6 67 67 44 97
Industries & Categories
Biopharma, Biotechnology, Oncology
Social Profiles
Canonical: https://fsome.com/organization/ervimmune-49100 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.